Pratik Dahiwale’s Post

Bayer and Zydus Group have been successful partners in India, with this Joint Venture contributing to Bayer’s strategy of significantly accelerating capabilities to better serve the fast-growing Indian market. It combined Zydus’s strong Indian marketing and sales expertise as well as excellent distribution and industry network, with Bayer’s global expertise in commercializing novel products and bringing in innovation to India. Bayer Zydus Pharma made remarkable strides in various therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology and oncology. We thank Zydus management team for being a remarkable partner for 13-years and building a partnership rested over trust, commitment and ownership. Moving forward, Bayer remains committed to ensuring its steadfast presence in India and continued focus on Advancing Innovation, Patient Centricity and Expanding Access. We look to build on the gains made over decades, as we surge forward in our mission of ‘Health for All, Hunger for None’. #BayerInIndia #BayerPharma #HealthforallHungerforNone

Please join me for a conversation today with the 5 leaders of our Indian Pharma industry

🚀 Exciting Transformation: Glenmark Life Sciences is Now Alivus Life Sciences! 🌟 We’re thrilled to announce that Glenmark Life Sciences has rebranded to Alivus Life Sciences Limited, marking a major milestone in our journey! This transformation comes following our acquisition by Nirma Limited, a leader in the consumer goods space, in March 2024. 🎉 What’s New? New Name**: Alivus Life Sciences reflects vitality, growth, and our commitment to delivering innovative solutions in the API and CDMO space. Ticker Symbol Update: As of January 20, 2025, our stock ticker has changed from GLS to **ALVUS. 🌐 Global Presence With 161 molecules in our portfolio and manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh, we supply high-quality APIs to global markets including India, Europe, North America, Latin America, and Japan. Our plants are regularly inspected by global regulatory authorities like the USFDA, PMDA (Japan), and EDQM (Europe)—ensuring high standards and quality. 📈 Financial Highlights (FY2025) Q2 Revenue**: ₹5,069 million H1 Revenue**: ₹10,955 million While challenges—such as the temporary closure of our Ankleshwar facility—impacted performance, a solid order book and improved gross margins set the stage for a strong recovery by the second half of FY2025. ✨ Looking Ahead Under our new identity as Alivus Life Sciences, we remain committed to enhancing our global presence and leading with innovation in the pharmaceutical industry. With strong demand across Europe and the U.S., we’re optimistic about the future and excited to continue delivering value to our customers, partners, and stakeholders. #Rebranding #AlivusLifeSciences #Innovation #Pharmaceuticals #Growth #APIs #GlobalLeadership

🌟 Unsung Business Series - Part 5 🌟 Today, let's shine a spotlight on a remarkable B2B healthcare technology company that has been quietly transforming the industry for over 25 years: Indegene. Founded in 1998 by Anand Kiran, Dr. Sanjay Parikh, Gaurav Kapoor, Dr. Rajesh Nair, and Manish Gupta, Indegene has recently made waves with its oversubscribed IPO (𝐛𝐲 52 𝐭𝐢𝐦𝐞𝐬), underscoring its position as a force to be reckoned with in the market. With a revenue of 1916 Cr and a PAT of 242 Cr, boasting a margin of 12.6%, Indegene is not just a player; it's a powerhouse. It's no surprise they've earned a spot on the 𝐅𝐨𝐫𝐭𝐮𝐧𝐞 𝟓𝟎𝟎 𝐍𝐞𝐱𝐭 list of India. Understanding Indegene's intricate business model may take some time due to its complexity, but in essence, they excel in helping biopharmaceutical companies launch medical assets and brands. With an impressive track record of assisting in the launch of 1.5 million medical assets and 750 brands, Indegene stands as a beacon of innovation and expertise in the field. Here are three key insights into their business: 𝐍𝐢𝐜𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: Indegene has strategically positioned itself as a global leader in digital enablement of life science commercialization. Their expertise in this niche market, requiring specialized skill sets honed over time, makes entry into this arena challenging for competitors. 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐏𝐫𝐨𝐩𝐞𝐫𝐭𝐲: Leveraging a global talent pool and specialized IP, Indegene offers a wide range of services spanning development, consulting, and co-commercialization for biopharmaceutical and emerging biotechnology companies. With recent acquisitions like Trilogy Writing & Consulting, Indegene is poised to deliver quality medical writing output, further solidifying its position in the market. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐫𝐞𝐬𝐞𝐧𝐜𝐞: With a robust global delivery footprint, Indegene caters to clients across all tiers of the pharmaceutical industry, from startups to established global players. Their proactive approach in offering innovative solutions to clients and their existing footprint in 𝟏𝟗 𝐨𝐮𝐭 𝐨𝐟 𝟐𝟎 global pharmaceutical companies showcase their commitment to being strategic partners in the industry. Indegene's recent acquisition of Trilogy Writing & Consulting reflects their commitment to growth and innovation in the ever-evolving healthcare landscape. As they continue to expand their offerings and global reach, Indegene is undoubtedly a company to watch closely in the years to come. #HealthcareTechnology #Biopharmaceutical #Indegene #BusinessInsights #IPO #HealthcareInnovation #FutureReadyHealthcare

💊 Piramal Pharma's Big Leap! On Thursday, Piramal Pharma reported an impressive over four-fold increase in consolidated net profit, reaching ₹23 crore for the second quarter ended September. A strong performance in the pharma sector! 📈💼 #PiramalPharma #Q2Results #ProfitGrowth #PharmaSector #FinancialNews #StockMarket #InvestmentNews #OptionPerks #EarningsUpdate

Eli Lilly and Merck in Hyderabad: Strengthens City's Pharma GCC Leadership 💠World's No.1 Life Sciences/Pharma Company "Eli Lilly" ($700+B M Cap) to setup its Global Capability/Technology Center in Hyderabad 💠 World's 5th Largest Pharma company Merck (MSD) announces its Technology center in Hyderabad (5th in the World) 💠Hyderabad is now home to the Global Capability Centers (GCCs) of 9 out of the world’s top 18 pharma and biotech companies. 💠Eli Lilly leases 2.1 lakh Sft in Phoenix Equinox in Hitec City (next to IKEA) 💠 Both are likely to start operation in 2025. MSD will be in Q1 2025 💠We had highly successful 2024 with Zoetis, Amgen Bristol Myers starting operations and Sanofi announcing major GCC expansion and these 2 new announcements Source Credits: Harikrish & Zaitsev333 -Skyscrapercity #indianpharma #gcc #happeninghyderabad

Indian Pharma in 2024: Navigating Challenges and Ensuring Survival for Small Companies The Indian pharmaceutical industry is a global leader in generics and supplies critical medications across the world. However, 2024 presents unique challenges for small and mid-sized pharma companies in India. Here, we explore the key hurdles and potential solutions for these companies to not only survive but also thrive in this competitive landscape. Challenges Faced by Small Pharma Companies in 2024: Intensified Competition: The Indian pharmaceutical market is witnessing a surge in competition from both domestic and international players. This saturation makes it difficult for smaller companies to differentiate their products and establish a strong brand presence. Price Control Measures: Government regulations aiming to make essential medicines affordable have led to price control on many drugs. This squeezes profit margins for small companies, making it challenging to invest in research and development (R&D) for new drugs. Stringent Regulatory Requirements: The regulatory environment for the pharmaceutical industry is becoming increasingly complex. Complying with these regulations can be a significant burden for smaller companies, diverting resources away from core activities. Survival Strategies for Small Pharma Companies: Innovation is Key: Focusing on niche markets and unmet medical needs can be a game-changer. Developing generics with improved delivery mechanisms or targeted drug combinations can create a competitive edge. Additionally, investing in R&D for new drugs, even if niche, can ensure future growth. Embrace Agility and Digitalization: The ability to adapt to the evolving regulatory landscape is crucial. Small companies should leverage digital tools for efficient operations, streamlined data management, and targeted marketing campaigns. This can help reduce costs and improve responsiveness to market changes. Collaboration is the Way Forward: Strategic partnerships with larger companies can be mutually beneficial. Small companies can leverage the reach and resources of larger players for distribution, marketing, or even joint research ventures. Mergers and acquisitions can also be a viable option to gain access to capital, expertise, and a wider product portfolio. Building Strong Relationships: Developing trust and fostering long-term relationships with healthcare providers (HCPs) is essential. By providing valuable solutions that address HCPs' needs and challenges, small companies can establish themselves as trusted partners in patient care. Conclusion: The Indian pharmaceutical industry is undergoing a period of transformation. While challenges exist, they also present opportunities for small companies to innovate, adapt, and collaborate. #IndianPharma #PharmaChallenges #Innovation #Collaboration #SmallPharma

🚀 Rebranding Announcement: Alivus Life Sciences – A Strategic Step Toward a Transformative Future 🌟 Glenmark Life Sciences has embarked on an inspiring journey of transformation, rebranding itself as Alivus Life Sciences under the ownership of Nirma Limited. This strategic move symbolizes a bold vision, focused on vitality, growth, and an enhanced global footprint in the Active Pharmaceutical Ingredients (API) and Contract Development & Manufacturing Organization (CDMO) space. 🧠 Here’s why this rebranding is a masterstroke: 1️⃣ Alignment with Ownership: The rebranding reflects its alignment with Nirma Limited’s diversified growth strategy, creating a unified identity that resonates with the parent company’s vision for innovation and expansion. 2️⃣ New Identity, Same Values: By adopting the name Alivus—symbolizing vitality and growth—the company positions itself as a forward-looking brand without losing its commitment to quality, innovation, and customer trust. 3️⃣ Targeted Industry Focus: A renewed focus on APIs and CDMO, particularly in chronic therapeutic areas, positions Alivus as a niche player delivering high-value, non-commoditized solutions—a key differentiator in a competitive market. 4️⃣ Global Credibility & Infrastructure: With four globally certified manufacturing facilities (USFDA, PMDA, EDQM) and an installed capacity of 1,424 KL, Alivus is well-equipped to strengthen its global partnerships and scale its operations. 5️⃣ Digital Transformation: Launching alivus.com as the new digital identity ensures a seamless transition while offering stakeholders easy access to updated services, branding, and initiatives. 6️⃣ Cultural Refresh: Rebranding provides an opportunity to inspire internal teams, boost morale, and drive alignment with the company's transformative goals—empowering employees to become brand ambassadors of this new chapter. Rebranding is not just a change of name—it’s a statement of intent. Alivus Life Sciences is poised to embrace the future with optimism, innovation, and a stronger commitment to excellence in the pharmaceutical industry. 💡 Let’s keep an eye on how Alivus Life Sciences drives its next phase of growth and impacts the global API and CDMO landscape. What are your thoughts on this rebranding strategy? Let’s discuss in the comments! 👇 #Rebranding #MarketingStrategy #Pharmaceuticals #APIs #CDMO #AlivusLifeSciences #Innovation #GlobalExpansion

🌟 India's Pharma Sector: Poised for Rapid Growth! 🌟 The Indian pharmaceutical industry is on the brink of transformation, with 86% of CXOs emphasizing the need for greater ecosystem collaboration, according to a new report by EY-Parthenon and OPPI India. 📈 The report highlights key growth drivers, including advancements in R&D, policy support, and innovation, which are set to shape the future of healthcare and pharma in India. It also calls for stronger partnerships between stakeholders to harness this potential effectively. Check out this insightful analysis on the next big wave in India's pharma sector! 🏥💊 Sushmita Panda Sakshi Kuchroo Sumana Sarkar Roshun Povaiah Syed Fazal Bari #PharmaGrowth #HealthcareInnovation #IndiaPharma #Collaboration

Join the IPSF Career Path Webinar Series and unlock your potential in the pharmaceutical industry!